Legal & General Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,646
| Closed | -$100K | – | 3780 |
|
|
2021
Q1 | $100K | Sell |
2,646
-2,846
| -52% | -$71K | ﹤0.01% | 2622 |
|
|
2020
Q4 | $93K | Buy |
5,492
+281
| +5% | +$3.52K | ﹤0.01% | 2607 |
|
|
2020
Q3 | $24K | Sell |
5,211
-1,156
| -18% | -$5.87K | ﹤0.01% | 2930 |
|
|
2020
Q2 | $38K | Sell |
6,367
-634
| -9% | -$2.61K | ﹤0.01% | 2810 |
|
|
2020
Q1 | $15K | Sell |
7,001
-1,130
| -14% | -$4.8K | ﹤0.01% | 3042 |
|
|
2019
Q4 | $37K | Sell |
8,131
-2,713
| -25% | -$10.7K | ﹤0.01% | 2950 |
|
|
2019
Q3 | $42K | Buy |
10,844
+2,846
| +36% | +$15.6K | ﹤0.01% | 2814 |
|
|
2019
Q2 | $48K | Sell |
7,998
-17,750
| -69% | -$170K | ﹤0.01% | 2795 |
|
|
2019
Q1 | $345K | Buy |
25,748
+13,510
| +110% | +$154K | ﹤0.01% | 2222 |
|
|
2018
Q4 | $114K | Hold |
12,238
| – | – | ﹤0.01% | 2427 |
|
|
2018
Q3 | $171K | Buy |
12,238
+562
| +5% | +$8.36K | ﹤0.01% | 2374 |
|
|
2018
Q2 | $185K | Sell |
11,676
-1,092
| -9% | -$19.1K | ﹤0.01% | 2315 |
|
|
2018
Q1 | $219K | Sell |
12,768
-790
| -6% | -$15.4K | ﹤0.01% | 2281 |
|
|
2017
Q4 | $298K | Buy |
13,558
+3,277
| +32% | +$105K | ﹤0.01% | 2213 |
|
|
2017
Q3 | $416K | Buy |
10,281
+826
| +9% | +$25.9K | ﹤0.01% | 2129 |
|
|
2017
Q2 | $288K | Buy |
9,455
+287
| +3% | +$8.96K | ﹤0.01% | 2184 |
|
|
2017
Q1 | $331K | Buy |
9,168
+2,583
| +39% | +$114K | ﹤0.01% | 2126 |
|
|
2016
Q4 | $332K | Buy |
6,585
+2,833
| +76% | +$149K | ﹤0.01% | 2087 |
|
|
2016
Q3 | $194K | Sell |
3,752
-325
| -8% | -$15.5K | ﹤0.01% | 2034 |
|
|
2016
Q2 | $169K | Buy |
4,077
+208
| +5% | +$9.05K | ﹤0.01% | 1841 |
|
|
2016
Q1 | $160K | Buy |
3,869
+527
| +16% | +$18.1K | ﹤0.01% | 1809 |
|
|
2015
Q4 | $137K | Hold |
3,342
| – | – | ﹤0.01% | 1909 |
|
|
2015
Q3 | $51K | Hold |
3,342
| – | – | ﹤0.01% | 2440 |
|
|
2015
Q2 | $81K | Hold |
3,342
| – | – | ﹤0.01% | 2272 |
|
|
2015
Q1 | $79K | Hold |
3,342
| – | – | ﹤0.01% | 2201 |
|
|
2014
Q4 | $90K | Hold |
3,342
| – | – | ﹤0.01% | 2066 |
|
|
2014
Q3 | $40K | Buy |
+3,342
| New | +$42.2K | ﹤0.01% | 2498 |
|
Legal & General Group's FPRX Position: Q2 2021 in Review
Legal & General Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,646 shares — an estimated $100K sold.
Legal & General Group first reported a position in FPRX in Q3 2014 and held it in 27 quarters. The position peaked at $416K in Q3 2017. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Legal & General Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Legal & General Group sold 2,646 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $100K.
- Legal & General Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 27 quarters.
- Legal & General Group's Five Prime Therapeutics, Inc. position peaked at $416K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.